跳至主要内容
临床试验/NCT00245934
NCT00245934已完成不适用

Observational Study With Enbrel in Patients With Rheumatoid Arthritis

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 1,500 人开始时间: 2003年6月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,500

研究概览

简要总结

The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Proven diagnosis of rheumatoid arthritis

排除标准

  • Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation:
  • Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®
  • Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections
  • Patients with sepsis or risk of sepsis should not be treated

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验